{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:08:22Z","timestamp":1791824902117,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,26]]},"DOI":"10.7759\/cureus.16635","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T12:20:31Z","timestamp":1627302031000},"source":"Crossref","is-referenced-by-count":38,"title":["Vaccine Development Throughout History"],"prefix":"10.7759","author":[{"given":"Amr","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahraz","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romil","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.060","article-title":"Vaccine history: the past as prelude to the future","volume":"30","author":"Artenstein AW","year":"2012","unstructured":"Artenstein AW, Poland GA. Vaccine history: the past as prelude to the future. Vaccine. 2012, 30:5299-5301. 10.1016\/j.vaccine.2012.06.060","journal-title":"Vaccine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2012.12k044","article-title":"The origins of inoculation","volume":"105","author":"Boylston A","year":"2012","unstructured":"Boylston A. The origins of inoculation. J R Soc Med. 2012, 105:309-313. 10.1258\/jrsm.2012.12k044","journal-title":"J R Soc Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany I","year":"2014","unstructured":"Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. 2014, 6:708-720. 10.1002\/emmm.201403876","journal-title":"EMBO Mol Med"},{"key":"ref4","unstructured":"History of smallpox. (2021). Accessed. April 7, 2021: https:\/\/www.cdc.gov\/smallpox\/history\/history.html."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1489724","article-title":"A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact","volume":"17","author":"Pindyck T","year":"2018","unstructured":"Pindyck T, Tate JE, Parashar UD. A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact. Expert Rev Vaccines. 2018, 17:593-606. 10.1080\/14760584.2018.1489724","journal-title":"Expert Rev Vaccines"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"S\u00e1nchez-Sampedro L","year":"2015","unstructured":"S\u00e1nchez-Sampedro L, Perdiguero B, Mej\u00edas-P\u00e9rez E, Garc\u00eda-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses. 2015, 7:1726-1803. 10.3390\/v7041726","journal-title":"Viruses"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s3687","article-title":"ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"Nalca A","year":"2010","unstructured":"Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Dev Ther. 2010, 4:71-79. 10.2147\/dddt.s3687","journal-title":"Drug Des Dev Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.08.050","article-title":"The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform","volume":"39","author":"Volkmann A","year":"2021","unstructured":"Volkmann A, Williamson AL, Weidenthaler H, et al.. The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. Vaccine. 2021, 39:3067-3080. 10.1016\/j.vaccine.2020.08.050","journal-title":"Vaccine"},{"key":"ref9","article-title":"Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC)","volume":"52","author":"Wharton M","year":"2003","unstructured":"Wharton M, Strikas RA, Harpaz R, et al.. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003, 52:1-16.","journal-title":"MMWR Recomm Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268815002198","article-title":"Prophylactic HPV vaccination: past, present, and future","volume":"144","author":"Castle PE","year":"2016","unstructured":"Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016, 144:449-468. 10.1017\/S0950268815002198","journal-title":"Epidemiol Infect"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.80.12.3812","article-title":"A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions","volume":"80","author":"D\u00fcrst M","year":"1983","unstructured":"D\u00fcrst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983, 80:3812-3815.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.059","article-title":"Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine","volume":"22","author":"Brown DR","year":"2004","unstructured":"Brown DR, Fife KH, Wheeler CM, et al.. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine. 2004, 22:2936-2942. 10.1016\/j.vaccine.2003.11.059","journal-title":"Vaccine"},{"key":"ref13","unstructured":"Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa. (2014). Accessed. April 11, 2021: https:\/\/www.who.int\/news\/item\/08-08-2014-statement-on-the-1st-meeting-of-the-ihr-emergency-committee-on-the-2014-ebol...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30476-x","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard AJ","year":"2021","unstructured":"Pollard AJ, Launay O, Lelievre JD, et al.. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021, 21:493-506. 10.1016\/s1473-3099(20)30476-x","journal-title":"Lancet Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo AM","year":"2015","unstructured":"Henao-Restrepo AM, Longini IM, Egger M, et al.. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015, 386:857-866. 10.1016\/s0140-6736(15)61117-5","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji ST","year":"2016","unstructured":"Agnandji ST, Huttner A, Zinser ME, et al.. Phase 1 trials of rVSV ebola vaccine in Africa and Europe. N Engl J Med. 2016, 374:1647-1660.","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"Ervebo EPAR. (2019). Accessed. April 11, 2021: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ervebo."},{"key":"ref18","unstructured":"First FDA-approved vaccine for the prevention of Ebola virus disease. (2019). Accessed. April 11, 2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking...."},{"key":"ref19","unstructured":"Mvabea. (2020). Accessed. April 11, 2021: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvabea."},{"key":"ref20","unstructured":"Zabdeno. (2020). Accessed. April 11, 2021: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zabdeno."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03981.x","article-title":"Rotavirus vaccination: a concise review","volume":"18","author":"Vesikari T","year":"2012","unstructured":"Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect. 2012, 18:57-63. 10.1111\/j.1469-0691.2012.03981.x","journal-title":"Clin Microbiol Infect"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1018","article-title":"The history of hepatitis A","volume":"16","author":"Shouval D","year":"2020","unstructured":"Shouval D. The history of hepatitis A. Clin Liver Dis (Hoboken). 2020, 16:12-23. 10.1002\/cld.1018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1769389","article-title":"Hepatitis A vaccination","volume":"16","author":"Zhang L","year":"2020","unstructured":"Zhang L. Hepatitis A vaccination. Hum vaccine Immunother. 2020, 16:1565-1573. 10.1080\/21645515.2020.1769389","journal-title":"Hum vaccine Immunother"},{"key":"ref24","article-title":"","author":"Kuhnert P","year":"2008","unstructured":"Kuhnert P, Christensen H. Pasteurellaceae: Biology, Genomics and Molecular Aspects. Kuhnert P, Christensen H (ed): Caister Academic Press, United Kingdom; 2008."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.063","article-title":"Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: patent landscaping and perspectives of developing country vaccine manufacturers","volume":"33","author":"Chandrasekharan S","year":"2015","unstructured":"Chandrasekharan S, Amin T, Kim J, Furrer E, Matterson AC, Schwalbe N, Nguyen A. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: patent landscaping and perspectives of developing country vaccine manufacturers. Vaccine. 2015, 33:6366-6370. 10.1016\/j.vaccine.2015.08.063","journal-title":"Vaccine"},{"key":"ref26","unstructured":"WHO Immunological Basis for Immunization Series. Module 9: Haemophilus influenzae type b. (2007). Accessed: April 16, 2021: https:\/\/www.who.int\/publications\/i\/item\/who-immunological-basis-for-immunization-series-module-9-haemophilus-influenz...."},{"key":"ref27","article-title":"History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines","volume":"57","author":"Barberis I","year":"2016","unstructured":"Barberis I, Myles P, Ault SK, Bragazzi NL, Martini M. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg. 2016, 57:E115-E120.","journal-title":"J Prev Med Hyg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.14.21253557","article-title":"Mortality and severity in COVID-19 patients on ACEIs & ARBs - a meta-regression analysis [PREPRINT]","author":"Singh R","year":"2021","unstructured":"Singh R, Rathore SS, Khan H, et al.. Mortality and severity in COVID-19 patients on ACEIs & ARBs - a meta-regression analysis [PREPRINT]. medRxiv. 2021, 10.1101\/2021.03.14.21253557","journal-title":"medRxiv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2174\/1874306402014010079","article-title":"Novel and controversial therapies in COVID-19","volume":"14","author":"Singh R","year":"2020","unstructured":"Singh R, Shaik L, Mehra I, Kashyap R, Surani S. Novel and controversial therapies in COVID-19. Open Respir Med J. 2020, 14:79-86. 10.2174\/1874306402014010079","journal-title":"Open Respir Med J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.08.21256845","article-title":"Association of obesity with COVID-19 severity and mortality: a systemic review and meta-regression [PREPRINT]","author":"Singh R","year":"2021","unstructured":"Singh R, Rathore SS, Khan H, et al.. Association of obesity with COVID-19 severity and mortality: a systemic review and meta-regression [PREPRINT]. medRxiv. 2021, 10.1101\/2021.05.08.21256845","journal-title":"medRxiv"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.606429","article-title":"Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis","volume":"7","author":"Bansal V","year":"2020","unstructured":"Bansal V, Mahapure KS, Bhurwal A, et al.. Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2020, 7:606429. 10.3389\/fmed.2020.606429","journal-title":"Front Med (Lausanne)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.624924","article-title":"Mortality benefit of convalescent plasma in COVID-19: a systematic review and meta-analysis","volume":"8","author":"Bansal V","year":"2021","unstructured":"Bansal V, Mahapure KS, Mehra I, et al.. Mortality benefit of convalescent plasma in COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021, 8:624924. 10.3389\/fmed.2021.624924","journal-title":"Front Med (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.30.21256415","article-title":"A meta-analysis of mortality, need for ICU admission, use of mechanical ventilation and adverse effects with ivermectin use in COVID-19 patients [PREPRINT]","author":"Karale S","year":"2021","unstructured":"Karale S, Bansal V, Makadia J, et al.. A meta-analysis of mortality, need for ICU admission, use of mechanical ventilation and adverse effects with ivermectin use in COVID-19 patients [PREPRINT]. medRxiv. 2021, 10.1101\/2021.04.30.21256415","journal-title":"medRxiv"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13894","article-title":"The association of acute kidney injury with disease severity and mortality in COVID-19: a systematic review and meta-analysis","volume":"13","author":"Menon T","year":"2021","unstructured":"Menon T, Sharma R, Kataria S, et al.. The association of acute kidney injury with disease severity and mortality in COVID-19: a systematic review and meta-analysis. Cureus. 2021, 13:e13894. 10.7759\/cureus.13894","journal-title":"Cureus"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13828","article-title":"Association of Guillain-Barre Syndrome with COVID-19: a case report and literature review","volume":"13","author":"Singh R","year":"2021","unstructured":"Singh R, Shiza ST, Saadat R, Dawe M, Rehman U. Association of Guillain-Barre Syndrome with COVID-19: a case report and literature review. Cureus. 2021, 13:e13828. 10.7759\/cureus.13828","journal-title":"Cureus"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13317","article-title":"Association of gastrointestinal system with severity and mortality of COVID-19: a systematic review and meta-analysis","volume":"13","author":"Menon T","year":"2021","unstructured":"Menon T, Sharma R, Earthineni G, et al.. Association of gastrointestinal system with severity and mortality of COVID-19: a systematic review and meta-analysis. Cureus. 2021, 13:e13317. 10.7759\/cureus.13317","journal-title":"Cureus"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8034","article-title":"A review of cardiac complications in coronavirus disease 2019","volume":"12","author":"Singh R","year":"2020","unstructured":"Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A review of cardiac complications in coronavirus disease 2019. Cureus. 2020, 12:e8034. 10.7759\/cureus.8034","journal-title":"Cureus"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.22541\/au.161219538.89676033\/v1","article-title":"Myocarditis associated with Covid-19 disease: a systematic review of published case reports and case series [PREPRINT]","author":"Rathore SS","year":"2021","unstructured":"Rathore SS, Rojas GA, Sondhi M, et al.. Myocarditis associated with Covid-19 disease: a systematic review of published case reports and case series [PREPRINT]. Authorea Preprints. 2021, 10.22541\/au.161219538.89676033\/v1","journal-title":"Authorea Preprints"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002662R","article-title":"COVID-19: current knowledge in clinical features, immunological responses, and vaccine development","volume":"35","author":"Singh R","year":"2021","unstructured":"Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, Xing Z. COVID-19: current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 2021, 35:21409. 10.1096\/fj.202002662R","journal-title":"FASEB J"},{"key":"ref40","unstructured":"COVID-19 vaccine Moderna. (2021). Accessed. April 17, 2021: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/covid-19-vaccine-moderna."},{"key":"ref41","unstructured":"Coronavirus disease (COVID-19). vaccines. (2020). Accessed: April 17, 2021: https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-(covid-19)-vaccines."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/64699-vaccine-development-throughout-history","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:07Z","timestamp":1707506887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/64699-vaccine-development-throughout-history"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.16635","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,26]]}}}